Significantly aggravating the clinical course and negatively affecting the quality of life of patients, voice disorders in acute respiratory viral infection (ARVI) and SARS-CoV-2 require correction of treatment. Aim. To determine the effectiveness of Homeovox® in the complex therapy of dysfunctions in patients with respiratory infections and SARS-CoV-2 Materials and methods. The clinical study was conducted by a single-stage observational method, without intervention, at the clinical base of the Department of Otorhinolaryngology of the South Ural State Medical University in the period 2022–2023. The results of a study of 45 patients who suffered from acute respiratory and coronavirus infection SARS-CoV-2, accompanied by dysphonia, are presented. Results. There was a significant difference in the results of conservative treatment of patients previously divided into 2 groups according to the study design. Thus, in the second group (n=22), in addition to medical and economic standards, who received a multicomponent homeopathic medicine in accordance with the instructions, earlier recovery periods and statistically reliable restoration of vocal function were established until complete restoration of vocal function. Standard medical and economical therapy of patients of the first (n=23) and second groups included: administration of antiviral and antihistamines, local decongestants, irrigation therapy, symptomatic treatment. Conclusion. The assessment of dysphonia on three scales: the VASH scale, the Wilson Yanagihara scale and the GRBAS classification of voice disorders confirmed the restoration of voice function and recovery at an earlier date in patients who additionally took a homeopathic drug